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Abstract
Background: Primary open-angle glaucoma (POAG) is the most common form of glaucoma which
is an irreversible blind leading disease and lacks effective remedies. In recent years, POAG has been
linked to the gene MYOC encoding myocilin that has been identified to harbor causal mutations. A
variety of studies show that the mutant myocilin acts by gain of function. The mutant MYOC protein
induces endoplasmic reticulum (ER) stress and the resultant unfolded protein response (UPR)
induces apoptosis in the trabecular meshwork cells, which then leads to an increase in resistance
to aqueous humor outflow, elevated intraocular pressure (IOP), and, ultimately, glaucoma.
Culturing human trabecular meshwork (HTM) cells at a condition facilitating protein folding
promotes secretion of mutant myocilin, normalizes cell morphology and reverses cell lethality.
Presentation of the Hypothesis: We speculate that a complete elimination of mutant myocilin
expression in trabecular meshwork cells is safe and that gives the possibility of avoiding the POAG
phenotype.
Testing the Hypothesis: We propose RNA interference (RNAi) as a gene silencing therapy to
eliminate the mutant myocilin proteins in the trabecular meshwork cells, either in a mutation-
dependent or mutation-independent way due to the different engineering of the small interfering
(si) RNA.
Implications of the Hypothesis: The RNAi strategy can reverse the pathological process of
trabecular meshwork cells and thus treat the POAG caused by myocilin gene mutation. This
strategy can also be applicable to many protein-misfolding diseases caused by gain-of-function
mutant proteins.
Background
Glaucoma is a group of progressive optic neuropathies
that have in common a slow progressive degeneration of
retinal ganglion cells and their axons, resulting in a dis-
tinct appearance of the optic disc and a concomitant pat-
tern of visual loss[1]. Without adequate treatment,
glaucoma can progress to irreversible visual disability and
eventual blindness [1]. Of the many types of glaucoma,
primary open angle glaucoma (POAG) is perhaps the
most common, particularly in populations of African
ancestry and European [2-4]. In most cases of POAG,
increased resistance to the outflow of aqueous humor
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results in a rise in intraocular pressure (IOP), which even-
tually leads to loss of retinal ganglion cells[5]. Though
Increased IOP has been proven to be the only treatable
risk factor for glaucoma, the biological basis of the disease
is not yet fully understood[1]. This may underlies that the
present treatment of POAG directed at lowering IOP[6]
does not seem to halt all cases of progression [7-10]. To
date, six loci (GLC1A-E) have been linked to POAG alone.
Among them, the gene MYOC  encoding myocilin has
been identified as harboring causal mutations, which are
responsible for 3-4% adult-onset POAG cases [11]. This
warrants the gene therapy which holds the promise for
curing the disease. Current investigations of gene therapy
mainly focus on the transfer and expression of genes
encoding IOP-lowering, neuroprotective gene products,
and/or, wound healing inhibitors[12], but do not really
emphasize a specific elimination of the causal mutant
proteins. Here we propose RNA interference (RNAi) as
gene silencing therapy for complete elimination of
mutant myocilin from human trabecular meshwork
(HTM) cells.
Presentation of Hypothesis
The human myocilin gene encodes a 504 amino acid glyc-
oprotein expressed extra- or intracellularly in almost every
ocular tissue[13,14] but predominantly in the trabecular
meshwork [15]which is a tissue provides major resistance
to the aqueous humor outflow pathway, and the tissue
involved in elevated IOP associated with glaucoma. How-
ever,  MYOC-null individuals (no matter mice [16] or
human beings [17,18] have normal eyes and intraocular
pressure. These individuals are both viable and fertile as
well [16-18]. Overexpression of wild type (WT) MYOC in
transgenic mice does not lead to any glaucomatous phe-
notype[19,20]. All these facts suggest that haploinsuffi-
ciency of MYOC  is not a critical mechanism in the
pathogenesis of POAG [16-20].
A variety of recent studies show that the mutant myocilin
acts in the HTM cells by gain of function[16,21-27]. It was
observed that, in culture media, very little to no mutant
myocilin associated with the development of glaucoma
was secreted out of the HTM cells, while WT and polymor-
phism variant myocilin were secreted normally[26]. Fur-
ther investigations found that the disease-causing
myocilin mutants were actually misfolded, were highly
aggregation-prone and accumulated in large aggregates or
formed heteromeric complexes with WT myocilin in the
endoplasmic reticulum (ER)[5,22,24,28]. The ER is
responsible for the synthesis, modification and delivery of
correctly folded proteins to their proper target sites.
Increased expression of mutant, folding-incompetent pro-
teins causes ER stress and an ER stress response, called the
unfolded protein response(UPR). The UPR is an adaptive
mechanism to return the ER to its normal physiological
state by upregulating the ER folding capacity and down-
regulating the biosynthetic load of the ER. When the UPR
does not remedy the stress situation, apoptosis is initiated
in higher eukaryotic organisms, presumably to eliminate
unhealthy cells [29]. In the case of MYOC-associated
POAG, the aggregates induced the unfolded protein
response proteins BiP and phosphorylated endoplasmic
reticulum-localized eukaryotic initiation factor-2_ kinase
(PERK) with the subsequent activation of caspases 12 and
3 and expression of C/EBP homologous protein (CHOP)/
GADD153, leading to abnormal HTM cell morphology
and cell apoptosis[24,28]. The progressive loss of HTM
cells due to apoptosis should accordingly diminish the
phagocytotic capacity of the remaining TM cell popula-
tion to clean the outflow drainage and eventually results
in humor outflow resistance and elevated IOP[24]. This is
consist with the electron microscopic findings from biop-
sies of POAG patients showing a reduction of TM cells as
well as thickened trabeculae and accumulation of sheath-
derived plaques [30-33].
Since the mutant myocilin induces ER stress and eventu-
ally leads to the apoptosis of HTM cells and hence the
pathogenesis of Myoc- associated glaucoma, a complete
elimination of mutant myocilin in HTM cells may disrupt
or even partly reverse the disease. In support of this pro-
posal are two major previous investigation findings: (1)
Culturing HTM cells at a condition facilitating protein
folding promotes secretion of mutant myocilin, normal-
izes cell morphology and reverses cell lethality[5], and (2)
MYOC-null individuals have no glaucomatous phenotype
and are both viable and fertile as well [16-18].
Testing the Hypothesis
To eliminate the mutant myocilin in HTM cells, RNAi can
be used as a powerful gene silencing method [34-37],
either in a mutation-dependent [38] or a mutation-inde-
pendent way [39]. In mutation dependent RNAi, a cus-
tomized double-stranded small interfering (si) RNA
targeting a mutant sequence is synthesized and conducted
by a plasmid to the HTM cell expressing the very mutant
myocilin. The siRNA can be engineered specifically to sup-
press the mutant alleles differing from WT alleles as little
as only a single nucleotide[38], so that the WT myocilin
can express normally in the heterozygotes without being
insulted. However, myocilin-associated POAG is intra-
genic heterogeneous [40] and customized siRNA inhibi-
tion targeting large numbers of individual mutations
would be costly. A more economical approach of muta-
tion-independent silencing will avoid this drawback. In
this approach, siRNA complementary to the untranslated
regions (UTRs) of the target mRNA is conducted to the
HTM cell and hence both the WT and mutant alleles
would be suppressed. Moreover, a replacement WT myo-
cilin gene with modified UTRs that is sparing from theDiagnostic Pathology 2009, 4:46 http://www.diagnosticpathology.org/content/4/1/46
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suppression can be generated and conducted into the cell,
allowing the expression of WT alleles while suppressing
that of the mutant ones simultaneously[39]. In the case of
MYOC-associated POAG, the insertion of the replacement
WT myocilin gene may be unnecessary for suppression of
myocilin gene totally limited to HTM cells might not lead
to pathological phenotypes. If such a suppression without
inserting the replacement WT gene is safe, the mutation-
independent strategy would probably be the best choice
among the above proposals.
Implications of the Hypothesis
In this article, we propose RNAi as a gene silencing ther-
apy for the MYOC-associated POAG. It has been demon-
strated by abundant researches [5,22,24,28] that mutant
myocilin proteins are insufficiently folded and accumu-
late in the ER, inducing UPR with subsequently activated
cell apoptosis. We hypothesize that if these mutant pro-
teins are suppressed by siRNA mediated RNAi, the cell
lesion would be reversed. To the best of our knowledge,
our idea of treating POAG by inhibiting the disease caus-
ing gene has not been stated before. Those investigated
strategies of gene therapy for glaucoma do not aim at the
disease causing mutants, but focus on inducing genes
compensating for the defects [12], which are actually the
modifications of contemporary treatments at the gene
level. Compared with this, the RNAi strategy we propose
here is more specific to the etiological factor and would
likely to be more effective. Shinohara et al [41]proposed a
hypothesis of treating the retinitis pigmentosa (RP) by
silencing the mutant rhodopsin in a allele-specific way.
However, since MYOC-null individuals have been
reported to be healthy, we suspect that totally suppressing
the myocilin without inserting a replacement WT myoci-
lin to HTM cells would be safe and economically feasible.
ER retention of mutant proteins has been implicated in
the pathogenesis of many ER storage diseases other than
POAG, including some inherited neurodegenerative dis-
orders like Alzheimer's disease [29]. The RNAi strategy
aiming at eliminating the misfolded mutant proteins can
also be applied to these disorders. Problems to be solved
are the safety and efficiency of RNAi. A highly efficient
siRNA should be chosen from a variety of candidates and
the side effects should be observed with caution by a series
of investigations before it can be carried out clinically.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ML conceived the hypothesis and drafted the manuscript;
JX conceived the hypothesis and gave modifications of the
manuscript; XC involved in drafting the manuscript; XS
revised the manuscript critically and gave final approval of
the version to be published
References
1. Weinreb RN, Khaw PT: Primary open-angle glaucoma.  Lancet
2004, 363:1711-1720.
2. Rahmani B, Tielsch JM, Katz J, Gottsch J, Quigley H, Javitt J, Sommer
A: The cause-specific prevalence of visual impairment in an
urban population. The Baltimore Eye Survey.  Ophthalmology
1996, 103:1721-1726.
3. Quigley HA, Vitale S: Models of open-angle glaucoma preva-
lence and incidence in the United States.  Invest Ophthalmol Vis
Sci 1997, 38:83-91.
4. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D: Variations
in primary open-angle glaucoma prevalence by age, gender,
and race: a Bayesian meta-analysis.  Invest Ophthalmol Vis Sci
2006, 47:4254-4261.
5. Liu Y, Vollrath D: Reversal of mutant myocilin non-secretion
and cell killing: implications for glaucoma.  Hum Mol Genet
2004, 13:1193-1204.
6. American Academy of Ophthalmology PPPC, Glaucoma Panel: Pre-
ferred practice pattern: primary open-angle glaucoma San Francisco, Calif:
American Academy of Ophthalmology; 2000. 
7. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller
JP, Parrish RK, Wilson MR, Gordon MO: The Ocular Hyperten-
sion Treatment Study: a randomized trial determines that
topical ocular hypotensive medication delays or prevents the
onset of primary open-angle glaucoma.  Arch Ophthalmol 2002,
120:701-713.
8. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M: Reduction of
intraocular pressure and glaucoma progression: results from
the Early Manifest Glaucoma Trial.  Arch Ophthalmol 2002,
120:1268-1279.
9. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA,
Mills RP: Interim clinical outcomes in the Collaborative Initial
Glaucoma Treatment Study comparing initial treatment
randomized to medications or surgery.  Ophthalmology 2001,
108:1943-1953.
10. The Advanced Glaucoma Intervention Study (AGIS): 4.
Comparison of treatment outcomes within race. Seven-year
results.  Ophthalmology 1998, 105:1146-1164.
1 1. F in g e r t  J H,  H é o n E,  L i e bma n n J M , Y a ma m ot o T , C r a i g  J E,  Ra i t  J,
Kawase K, Hoh ST, Buys YM, Dickinson J, Hockey RR, Williams-Lyn
D, Trope G, Kitazawa Y, Ritch R, Mackey DA, Alward WL, Sheffield
VC, Stone EM: Analysis of myocilin mutations in 1703 glau-
coma patients from five different populations.  Hum Mol Genet
1999, 8:899-905.
12. Borras T, Brandt CR, Nickells R, Ritch R: Gene therapy for glau-
coma: treating a multifaceted, chronic disease.  Invest Ophthal-
mol Vis Sci 2002, 43:2513-2518.
13. Karali A, Russell P, Stefani FH, Tamm ER: Localization of myocilin/
trabecular meshwork--inducible glucocorticoid response
protein in the human eye.  Invest Ophthalmol Vis Sci 2000,
41:729-740.
14. Swiderski RE, Ross JL, Fingert JH, Clark AF, Alward WL, Stone EM,
Sheffield VC: Localization of MYOC transcripts in human eye
and optic nerve by in situ hybridization.  Invest Ophthalmol Vis Sci
2000, 41:3420-3428.
15. Adam MF, Belmouden A, Binisti P, Brézin AP, Valtot F, Béchetoille A,
Dascotte JC, Copin B, Gomez L, Chaventré A, Bach JF, Garchon HJ:
Recurrent mutations in a single exon encoding the evolu-
tionarily conserved olfactomedin-homology domain of TIGR
in familial open-angle glaucoma.  Hum Mol Genet 1997,
6:2091-2097.
16. Kim BS, Savinova OV, Reedy MV, Martin J, Lun Y, Gan L, Smith RS,
Tomarev SI, John SW, Johnson RL: Targeted Disruption of the
Myocilin Gene (Myoc) Suggests that Human Glaucoma-
Causing Mutations Are Gain of Function.  Mol Cell Biol 2001,
21:7707-7713.
17. Pang CP, Leung YF, Fan B, Baum L, Tong WC, Lee WS, Chua JK, Fan
DS, Liu Y, Lam DS: TIGR/MYOC gene sequence alterations in
individuals with and without primary open-angle glaucoma.
Invest Ophthalmol Vis Sci 2002, 43:3231-3235.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Diagnostic Pathology 2009, 4:46 http://www.diagnosticpathology.org/content/4/1/46
Page 4 of 4
(page number not for citation purposes)
18. Wiggs JL, Vollrath D: Molecular and clinical evaluation of a
patient hemizygous for TIGR/MYOC.  Arch Ophthalmol 2001,
119:1674-1678.
19. Gould DB, Miceli-Libby L, Savinova OV, Torrado M, Tomarev SI,
Smith RS, John SW: Genetically increasing Myoc expression
supports a necessary pathologic role of abnormal proteins in
glaucoma.  Mol Cell Biol 2004, 24:9019-9025.
20. Zillig M, Wurm A, Grehn FJ, Russell P, Tamm ER: Overexpression
and properties of wild-type and Tyr437His mutated myocilin
in the eyes of transgenic mice.  Invest Ophthalmol Vis Sci 2005,
46:223-234.
21. Caballero M, Rowlette LL, Borras T: Altered secretion of a TIGR/
MYOC mutant lacking the olfactomedin domain.  Biochim Bio-
phys Acta 2000, 1502:447-460.
22. Caballero M, Borras T: Inefficient processing of an olfactome-
din-deficient myocilin mutant: potential physiological rele-
vance to glaucoma.  Biochem Biophys Res Commun 2001,
282:662-670.
23. Sohn S, Hur W, Joe MK, Kim JH, Lee ZW, Ha KS, Kee C: Expression
of wild-type and truncated myocilins in trabecular mesh-
work cells: their subcellular localizations and cytotoxicities.
Invest Ophthalmol Vis Sci 2002, 43:3680-3685.
24. Joe MK, Sohn S, Hur W, Moon Y, Choi YR, Kee C: Accumulation
of mutant myocilins in ER leads to ER stress and potential
cytotoxicity in human trabecular meshwork cells.  Biochem
Biophys Res Commun 2003, 312:592-600.
25. Gobeil S, Rodrigue MA, Moisan S, Nguyen TD, Polansky JR, Moris-
sette J, Raymond V: Intracellular sequestration of hetero-oli-
gomers formed by wild-type and glaucoma-causing myocilin
mutants.  Invest Ophthalmol Vis Sci 2004, 45:3560-3567.
26. Jacobson N, Andrews M, Shepard AR, Nishimura D, Searby C, Fingert
JH, Hageman G, Mullins R, Davidson BL, Kwon YH, Alward WL,
Stone EM, Clark AF, Sheffield VC: Non-secretion of mutant pro-
teins of the glaucoma gene myocilin in cultured trabecular
meshwork cells and in aqueous humor.  Hum Mol Genet 2001,
10:117-125.
27. Gobeil S, Letartre L, Raymond V: Functional analysis of the glau-
coma-causing TIGR/myocilin protein: integrity of amino-ter-
minal coiled-coil regions and olfactomedin homology
domain is essential for extracellular adhesion and secretion.
Exp Eye Res 2006, 82:1017-1029.
28. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J: Aggregated myo-
cilin induces russell bodies and causes apoptosis: implica-
tions for the pathogenesis of myocilin-caused primary open-
angle glaucoma.  Am J Pathol 2007, 170:100-109.
29. Schroder M, Kaufman RJ: ER stress and the unfolded protein
response.  Mutat Res 2005, 569:29-63.
30. Alvarado J, Murphy C, Juster R: Trabecular meshwork cellularity
in primary open-angle glaucoma and nonglaucomatous nor-
mals.  Ophthalmology 1984, 91:564-579.
31. Alvarado JA, Yun AJ, Murphy CG: Juxtacanalicular tissue in pri-
mary open angle glaucoma and in nonglaucomatous nor-
mals.  Arch Ophthalmol 1986, 104:1517-1528.
32. Lutjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW: Quantitative
analysis of 'plaque material' in the inner- and outer wall of
Schlemm's canal in normal- and glaucomatous eyes.  Exp Eye
Res 1986, 42:443-455.
33. Rohen JW, Lutjen-Drecoll E, Flugel C, Meyer M, Grierson I:
Ultrastructure of the trabecular meshwork in untreated
cases of primary open-angle glaucoma (POAG).  Exp Eye Res
1993, 56:683-692.
34. Novina CD, Sharp PA: The RNAi revolution.  Nature 2004,
430:161-164.
35. Sontheimer EJ, Carthew RW: Molecular biology. Argonaute
journeys into the heart of RISC.  Science 2004, 305:1409-1410.
36. Caplen NJ: Gene therapy progress and prospects. Downregu-
lating gene expression: the impact of RNA interference.
Gene Ther 2004, 11:1241-1248.
37. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T:
Duplexes of 21-nucleotide RNAs mediate RNA interference
in cultured mammalian cells.  Nature 2001, 411:494-498.
38. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL, Paul-
son HL: Allele-specific silencing of dominant disease genes.
Proc Natl Acad Sci USA 2003, 100:7195-7200.
39. Kiang AS, Palfi A, Ader M, Kenna PF, Millington-Ward S, Clark G,
Kennan A, O'reilly M, Tam LC, Aherne A, McNally N, Humphries P,
Farrar GJ: Toward a gene therapy for dominant disease: vali-
dation of an RNA interference-based mutation-independent
approach.  Mol Ther 2005, 12:555-561.
40. Fingert JH, Stone EM, Sheffield VC, Alward WL: Myocilin glau-
coma.  Surv Ophthalmol 2002, 47:547-561.
41. Shinohara T, Mulhern ML, Madson CJ: Silencing gene therapy for
mutant membrane, secretory, and lipid proteins in retinitis
pigmentosa (RP).  Med Hypotheses 2008, 70:378-380.